Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access

Ian Hirsch¹, Daniel A Goldstein^{2

3}, Ian F Tannock^{1

3}, Marcus O Butler¹, Duncan C Gilbert^{4

5}

Affiliations

¹ Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
² Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
³ Optimal Cancer Care Alliance, Ann Arbor, MI, USA.
⁴ Optimal Cancer Care Alliance, Ann Arbor, MI, USA. duncan.gilbert@ucl.ac.uk.
⁵ MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK. duncan.gilbert@ucl.ac.uk.

Ian Hirsch et al. Nat Med. 2022 Nov.

. 2022 Nov;28(11):2236-2237.

doi: 10.1038/s41591-022-02029-1.

Ian Hirsch¹, Daniel A Goldstein^{2

3}, Ian F Tannock^{1

3}, Marcus O Butler¹, Duncan C Gilbert^{4

5}

¹ Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
² Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
³ Optimal Cancer Care Alliance, Ann Arbor, MI, USA.
⁴ Optimal Cancer Care Alliance, Ann Arbor, MI, USA. duncan.gilbert@ucl.ac.uk.
⁵ MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK. duncan.gilbert@ucl.ac.uk.

No abstract available

References

1. Patnaik, A. et al. Clin. Cancer Res. 21, 4286–4293 (2015). - DOI - PubMed
1. Lindauer, A. et al. CPT Pharmacometrics Syst. Pharmacol. 6, 11–20 (2017). - DOI - PubMed
1. Agrawal, S., Feng, Y., Roy, A., Kollia, G. & Lestini, B. J. Immunother. Cancer 4, 72 (2016). - DOI
1. Yoo, S. H. et al. ESMO Open 3, e000297 (2018). - DOI
1. Postow, M. A. et al. J. Clin. Oncol. 40, 1059–1067 (2021). - DOI - PubMed